文献速递血栓与止血

氨苯砜治疗成人原发性免疫性血小板减少症的疗效与安全性

Efficacy and safety of dapsone in adult primary immune thrombocytopenia.
PubMed 文献 · Blood Adv · 2025-01-01

一项多中心随机对照试验和一项真实世界队列研究评估氨苯砜在成人原发性免疫性血小板减少症(ITP)中的疗效与安全性。随机对照试验中,A组52周缓解率为21.7%(95%CI 10.9-36.4),B组为8.5%(95%CI 2.7-18.6),P=0.17;观察性研究中13.6%(95%CI 5.2-27.4)达到主要疗效终点。两项研究均显示氨苯砜风险获益比不利,提示若有其他二线选择应优先使用。

要点

  • 随机对照试验A组52周缓解率21.7% vs B组8.5%,差异无统计学显著(P=0.17)。
  • A组78.3%患者因不良事件或疗效不足在中位4.6周停用氨苯砜。
  • 观察性研究不良事件发生率30.4%,23.9%因不良事件停用氨苯砜。

核心结论

  • 两项研究结果均显示氨苯砜用于成人原发性ITP的风险获益比不利,提示若有其他二线选择应优先使用。

研究设计与样本

  • 多中心随机对照试验(RCT)联合真实世界队列研究;RCT纳入93例成人原发性ITP患者(54.8%女性),中位年龄48.5岁(A组46岁,B组47岁),随机分为A组(泼尼松×3周+氨苯砜12个月)或B组(单用泼尼松);观察性研究在RCT结束后开展,纳入46例患者(52.2%女性),中位年龄50.7岁,氨苯砜起始剂量100 mg/d并标准随访。

主要发现

  • RCT意向性治疗分析中,A组78.3%患者在中位4.6周停用氨苯砜,其中因不良事件停药占66.7%,因疗效不足停药占33.3%。
  • RCT第52周缓解率A组为21.7%(95%CI 10.9-36.4),B组为8.5%(95%CI 2.7-18.6),P=0.17。
  • 观察性研究中不良事件发生率为30.4%,导致23.9%患者停用氨苯砜,13.6%(95%CI 5.2-27.4)达到主要疗效终点。

关键数值与推荐

  • 主要终点为第52周缓解率,缓解定义为血小板计数>30×10^9/L且≥2倍基线水平;次要终点包括第24周缓解率和不良事件。
  • RCT入组标准为成人原发性ITP、对糖皮质激素(联合或不联合静脉注射免疫球蛋白)短暂有效、血小板计数≤30×10^9/L(或≤50×10^9/L伴出血)。

临床怎么用

  • 原文结论提示氨苯砜用于成人原发性ITP风险获益比不利,若有其他二线选择应优先使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To assess efficacy and safety of dapsone in adult immune thrombocytopenia (ITP), a multicenter randomized controlled trial (RCT) and a real-world cohort study were performed. Participants were adults with primary ITP, transient response to corticosteroids with/without intravenous immunoglobulin, and a platelet count of ≤30 × 109/L (or ≤50 × 109/L with bleeding). Patients in the RCT were randomized in arm A (prednisone × 3 weeks + dapsone for 12 months) or arm B (prednisone alone). The observational study involved dapsone initiation at 100 mg/d with standard follow-up. The primary end point was the response rate (platelet count of >30 × 109/L and ≥2× baseline level) at 52 weeks, with the response rate at 24 weeks and adverse events as secondary end points. The RCT enrolled 93 patients (54.8% female), with median age of 48.5 years (46 years in arm A; and 47 years in arm B). In the intention-to-treat analysis, 78.3% of patients in arm A discontinued dapsone after a median of 4.6 weeks because of adverse events (66.7%) or lack of efficacy (33.3%). The response rate at week 52 was 21.7% (95% confidence interval [CI], 10.9-36.4) in arm A vs 8.5% (95% CI, 2.7-18.6) in arm B (P = .17). The observational study, which was conducted after the end of the RCT, included 46 patients (52.2% female), median age of 50.7 years. Adverse events occurred in 30.4%, leading to discontinuation of dapsone in 23.9%, and 13.6% (95% CI 5.2-27.4) met the primary efficacy end point. Results from both studies showed an unfavorable risk-benefit ratio for the use of dapsone in adult primary ITP and suggest that, whenever available, second-line options should be used. This trial was registered at www.ClinicalTrials.gov as #NCT02627417 and #NCT02877706.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Larue M, Moulis G, Rueter M, et al. Efficacy and safety of dapsone in adult primary immune thrombocytopenia. Blood Adv. 2025. PMID: 39874521. doi:10.1182/bloodadvances.2024014939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。